Toripalimab plus IMRT | |
Overall response at 3 months post radiotherapy* | N=24 |
Overall response | 19 (79.2%; 95% CI 59.5% to 90.8%) |
Disease control | 23 (95.8%) |
Complete response | 11 (45.8%) |
Partial response | 8 (33.3%) |
Stable disease | 4 (16.7%) |
Progressive disease | 1 (4.2%) |
Best overall response after radiotherapy | N=25 |
Overall response | 23 (92.0%; 95% CI 75.0% to 97.8%) |
Disease control | 25 (100.0%) |
Complete response | 18 (72.0%) |
Partial response | 5 (20.0%) |
Stable disease | 2 (8.0%) |
Progressive disease | 0 (0.0%) |
Time to response, months | 2.65 (1.88–5.27) |
Median duration of response, months (IQR) | NR (NR-NR) |
Progression-free survival (PFS) | |
Failure | 5 |
Median PFS, months (95% CI) | 18.67 (12.04 to 25.29) |
PFS rate at 12 months (95% CI) | 91.8% (91.7% to 91.9%) |
*As there was one patient who did not undergo radiology examination for tumor response evaluation at 3 months post radiotherapy, a total of 24 patients were included in the analysis of overall response at 3 months post radiotherapy.
IMRT, intensity-modulated radiotherapy .